Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Status:
Terminated
Trial end date:
2017-02-21
Target enrollment:
Participant gender:
Summary
The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to
achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting
GLP-1 analog.
Patients who fail to achieve significant improvement in diabetes control on basal insulin and
Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The
primary outcomes will be changes in HBA1C and weight.